ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRY ARS PHARMACEUTICALS INC

Market Closed 01-23 16:00:00 EST

10.21

-0.36

-3.41%

盘后10.21

+0.000.00%

19:13 EST

High10.88	Low10.21	Vol1.47M
Open10.50	D1 Closing10.57	Amplitude6.34%
Mkt Cap1.01B	Tradable Cap564.31M	Total Shares98.85M
T/O15.34M	T/O Rate2.66%	Tradable Shares55.27M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":10.21,"timestamp":1769202000000,"preClose":10.57,"halted":0,"volume":1468250,"hourTrading":{"tag":"盘后","latestPrice":10.21,"preClose":10.21,"latestTime":"19:13 EST","volume":39579,"amount":403081.71,"timestamp":1769213601970,"change":0,"changeRate":0,"amplitude":0.060725},"delay":0,"changeRate":-0.034058656575212815,"floatShares":55270496,"shares":98848611,"eps":-0.81541,"marketStatus":"Market Closed","change":-0.36,"latestTime":"01-23 16:00:00 EST","open":10.5,"high":10.88,"low":10.21,"amount":15337503.943999998,"amplitude":0.063387,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.81541,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":7,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":10.57,"preHourTrading":{"tag":"盘前","latestPrice":10.76,"preClose":10.57,"latestTime":"08:54 EST","volume":180,"amount":1939.6416599999998,"timestamp":1769176478194,"change":0.19,"changeRate":0.017975,"amplitude":0.020464},"postHourTrading":{"tag":"盘后","latestPrice":10.21,"preClose":10.21,"latestTime":"19:13 EST","volume":39579,"amount":403081.71,"timestamp":1769213601970,"change":0,"changeRate":0,"amplitude":0.060725},"volumeRatio":1.1724687332261112,"impliedVol":1.0647,"impliedVolPercentile":0.8048},"requestUrl":"/m/hq/s/SPRY/tweets","defaultTab":"tweets","newsList":[{"id":"2605107172","title":"ARS Pharmaceuticals announces California eligible for neffyinSchools program","url":"https://stock-news.laohu8.com/highlight/detail?id=2605107172","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605107172?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:10","pubTimestamp":1769001051,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) announced that California is now eligible for its neffyinSchools program. “One year ago, we envisioned a nationwide prog...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-announces-california-eligible-for-neffyinschools-program-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-announces-california-eligible-for-neffyinschools-program-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2603253415","title":"ARS Pharmaceuticals Down Over 13%, on Pace for Largest Percent Decrease Since March -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2603253415","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603253415?lang=en_us&edition=fundamental","pubTime":"2026-01-13 04:16","pubTimestamp":1768248960,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals, Inc.  is currently at $11.36, down $1.70 or 13.02%. --On pace for largest percent decrease since March 21, 2025, when it fell 13.63%. --Down 81.2% from its all-time closing high of $60.41 on March 17, 2021. --Up 0.89% from 52 weeks ago , when it closed at $11.26. --Down 38.09% from its 52-week closing high of $18.35 on July 28, 2025. --Down 14.24% at today's intraday low; largest intraday percent decrease since Aug. 29, 2025, when it fell as much as 14.62%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2602707370","title":"Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2602707370","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602707370?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:28","pubTimestamp":1767976080,"startTime":"0","endTime":"0","summary":"Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug application, raising approval delay concerns despite the review remaining active.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/09/Peanut-Allergy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/09/Peanut-Allergy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/01/49817029/aquestive-stock-slides-after-fda-flags-issues-with-allergy-drug-application","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/01/49817029/aquestive-stock-slides-after-fda-flags-issues-with-allergy-drug-application","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","BK4007","AQST","SPRY"],"gpt_icon":0},{"id":"2602372459","title":"ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2602372459","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602372459?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:40","pubTimestamp":1767969636,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals’ (SPRY) competitor Aquestive Therapeutics (AQST) received an FDA letter citing NDA deficiencies for Anaphylm, preventing discus...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-competitor-gets-fda-deficiency-letter-says-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-competitor-gets-fda-deficiency-letter-says-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B64PRP62.GBP","LU2265009873.SGD","SPRY","LU1363072403.SGD","BK4588","BK4007","LU0971096721.USD","AQST","LU1804176565.USD","BK4585","BK4139","IE00B3QW5Z07.USD","BK4127","RJF","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2595718120","title":"ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy","url":"https://stock-news.laohu8.com/highlight/detail?id=2595718120","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595718120?lang=en_us&edition=fundamental","pubTime":"2025-12-30 18:26","pubTimestamp":1767090369,"startTime":"0","endTime":"0","summary":"The fact that multiple ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY ) insiders offloaded a considerable amount of shares...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-spry/ars-pharmaceuticals/news/ars-pharmaceuticals-insiders-sold-us13m-of-shares-suggesting","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-spry/ars-pharmaceuticals/news/ars-pharmaceuticals-insiders-sold-us13m-of-shares-suggesting","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2595802397","title":"China Approves ARS Pharmaceuticals' Neffy as First Community Use Epinephrine Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2595802397","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595802397?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013225,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. announced that its product neffy  has been approved in China as the first and only community use epinephrine product for the treatment of allergic reactions . This approval allows adults and children over 30 kg living with severe allergic reactions to access epinephrine outside of hospital settings for the first time in China. Under an exclusive licensing agreement, Pediatrix Therapeutics holds the rights to commercialize neffy in China and plans to make the product available in the spring of 2026. ARS Pharma will receive a final regulatory milestone payment of $4 million and is eligible for up to $80 million in sales milestones, in addition to tiered royalties on annual net sales.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL7dljB5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","BK4139","LU2095319765.USD","BK4585","SPRY","BK4588","LU2210149790.SGD","BK4112","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2595802567","title":"ARS Pharmaceuticals Inc - to Supply Neffy in China by Spring 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2595802567","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595802567?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA1HZTW8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2595780213","title":"ARS Pharmaceuticals - to Receive $4 Mln Regulatory Milestone and Is Eligible to Receive up to $80 Mln in Sales Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595780213?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA1HZTW8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2595778043","title":"Neffy® (Epinephrine Nasal Spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (Anaphylaxis)","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595778043?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA1HZTW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2583068007","title":"ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583068007","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583068007?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:43","pubTimestamp":1763163801,"startTime":"0","endTime":"0","summary":"Justin Chakma, Chief Business Officer of ARS Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL1Z85Gr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2583208509","title":"ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $25 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2583208509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583208509?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:33","pubTimestamp":1763127184,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ0Z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"1189977586","title":"Stock Track | ARS Pharmaceuticals Surges 7.34% Pre-Market on Strong Q3 Revenue, Despite Wider Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1189977586","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189977586?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:38","pubTimestamp":1762778319,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. (NASDAQ: SPRY) saw its stock soar 7.34% in pre-market trading on Monday following the release of its third-quarter 2025 financial results. The biopharmaceutical company,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"1113100917","title":"Stock Track | ARS Pharmaceuticals Soars 7.34% Pre-Market on Strong Q3 Results and neffy Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1113100917","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113100917?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:38","pubTimestamp":1762778304,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. (NASDAQ: SPRY) stock surged 7.34% in pre-market trading on Monday following the release of its third-quarter 2025 financial results, which showcased strong revenue growth and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SPRY"],"gpt_icon":0},{"id":"2582982031","title":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2582982031","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582982031?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:11","pubTimestamp":1762773110,"startTime":"0","endTime":"0","summary":"Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2582827210","title":"ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827210","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827210?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772450,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.47) by 10.17 percent. This is a 160 percent decrease over losses of $(0.20) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48746889/ars-pharmaceuticals-q3-eps-0-52-misses-0-47-estimate-sales-32-501m-beat-28-743m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2582449827","title":"ARS Pharmaceuticals Q3 Net Income USD -51.151 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582449827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582449827?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX59838A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2582827267","title":"ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights  for Neffy® (Epinephrine Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827267?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA6TWGML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2582827905","title":"Press Release: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy(R) (epinephrine nasal spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827905","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827905?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772400,"startTime":"0","endTime":"0","summary":"$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025. Continued U.S. product growth driven by direct-to-consumer  investments and real-world evidence, expected to accelerate with seamless prescribing experience. Strong balance sheet of $288.2 million cash, cash equivalents and short-term investments anticipated to fund operations through cash-flow break-even. \"We are executing our commercial strategy across multiple fronts, with each element reinforcing the others to drive momentum,\" said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma. \"Our direct-to-consumer campaigns are generating measurable increases in patient awareness; real-world evidence data are further strengthening prescriber confidence in neffy's effectiveness; and we are implementing advertising programs such as a free virtual prescriber option and zero dollar co-pay to further reduce barriers for patients, so that when healthcare providers want their ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4139","BK4585","BK4203","NHI","BK4500","BK4008","BK4022","BK4588","BK4232","SPRY","BK4225","R","EMA","BK4023","HCP","ALK"],"gpt_icon":0},{"id":"2580373141","title":"ARS Pharma Launches GET Neffy® on US for Patients With Severe Allergic Reactions to Improve Access to Neffy (Epinephrine Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580373141","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580373141?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261210,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA3HTWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2580731792","title":"ARS Pharmaceuticals resumed with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731792","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731792?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:55","pubTimestamp":1762260928,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Kyle Bauser resumed coverage of ARS Pharmaceuticals (SPRY) with a Buy rating and $30 price target The firm is anticipating sig...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-resumed-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-resumed-with-a-buy-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ars-pharma.com","stockEarnings":[{"period":"1week","weight":-0.0395},{"period":"1month","weight":-0.1106},{"period":"3month","weight":0.1207},{"period":"6month","weight":-0.4287},{"period":"1year","weight":-0.2649},{"period":"ytd","weight":-0.1236}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.045507},{"month":2,"riseRate":0.6,"avgChangeRate":0.08605},{"month":3,"riseRate":0.4,"avgChangeRate":-0.024933},{"month":4,"riseRate":0.2,"avgChangeRate":-0.083829},{"month":5,"riseRate":0.8,"avgChangeRate":0.021109},{"month":6,"riseRate":0.6,"avgChangeRate":0.093442},{"month":7,"riseRate":0.8,"avgChangeRate":0.11695},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080641},{"month":9,"riseRate":0.2,"avgChangeRate":-0.212128},{"month":10,"riseRate":0.4,"avgChangeRate":-0.021216},{"month":11,"riseRate":0.4,"avgChangeRate":0.043601},{"month":12,"riseRate":0.6,"avgChangeRate":0.080317}],"exchange":"NASDAQ","name":"ARS PHARMACEUTICALS INC","nameEN":"ARS PHARMACEUTICALS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ARS PHARMACEUTICALS INC,SPRY,ARS PHARMACEUTICALS INC股票,ARS PHARMACEUTICALS INC股票老虎,ARS PHARMACEUTICALS INC股票老虎国际,ARS PHARMACEUTICALS INC行情,ARS PHARMACEUTICALS INC股票行情,ARS PHARMACEUTICALS INC股价,ARS PHARMACEUTICALS INC股市,ARS PHARMACEUTICALS INC股票价格,ARS PHARMACEUTICALS INC股票交易,ARS PHARMACEUTICALS INC股票购买,ARS PHARMACEUTICALS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}